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Abstract
© 2017 Bentham Science Publishers.  The mammalian immune system is  a  nearly  perfect
defensive  system polished  by  a  hundred  million  years  of  evolution.  Unique  flexibility  and
adaptivity have created a virtually impenetrable barrier to numerous exogenous pathogens that
are assaulting us every moment.  Unfortunately,  triggers that remain mostly enigmatic will
sometimes  persuade  the  immune  system to  retarget  against  self-antigens.  This  civil  war
remains underway, showing no mercy and taking no captives, eventually leading to irreversible
pathological  changes in the human body.  Research that  has emerged during the last  two
decades has given us hope that we may have a chance to overcome autoimmune diseases
using a variety of techniques to "reset" the immune system. In this report, we summarize recent
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